NCT00185445已完成2 期
A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
Genzyme, a Sanofi Company0 个研究点目标入组 62 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
- 主要终点
- Complete response rate
研究概览
简要总结
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile
详细描述
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Indolent B-cell follicular non-Hodgkin's lymphoma (grade I-II according to REAL classification)
- •Stage II to IV according to Ann Arbor staging system
- •WHO performance status grade 0, 1 or 2 and life expectancy of greater than 6 months
排除标准
- •Patients who have received any previous treatment for follicular NHL
- •Patients with severe or life-threatening cardiac, pulmonary, neurological, psychiatric or metabolic disease
- •Pregnant and lactating women
- •Women of childbearing potential, and all men, not agreeing to take adequate contraceptive precautions during and for at least 6 months after cessation of therapy
- •Laboratory screens positive for Hepatitis B, C or HIV infections
- •Patients with autoimmune thrombocytopenia or hemolytic anemia with clinical evidence. NB. A positive Coombs test alone (with no clinical evidence of hemolysis) would not preclude entry in the study.
- •Histological transformation to aggressive B-cell lymphoma
- •Patients with prior malignancies except non melanoma skin tumors or stage 0 (in situ) cervical carcinoma
- •Impairment of hepatic function unless disease related indicated by bilirubin, ASAT, ALAT or gamma-GT raised 2 times above the upper limit of the local laboratory range
- •Impairment of renal function indicated by serum creatinine < 30 ml/min
- •Patients who require systemic long-term therapy with glucocorticoids
- •Participation at the same time in another study in which investigational drugs are used
- •Patients unable to regularly attend outpatient clinic for treatment and assessments
- •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
- •Patients with active infection
研究组 & 干预措施
Arm 1
Experimental
干预措施: Fludarabine Phosphate (Fludara) (Drug)
结局指标
主要结局
Complete response rate
时间窗: Measurement of outcome 4 to 6 weeks after EOT
次要结局
- Overall response rate, molecular response rate, toxicity profile, patients quality of life(Measurement of outcome 4 to 6 weeks after EOT)
研究者
相似试验
已完成
4 期
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or ThrombocytopeniaLeukemia, Lymphocytic, Chronic, B-CellNCT00220311Genzyme, a Sanofi Company10
终止
2 期
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.Acute Myeloid Leukemia, AdultAML, AdultAMLNCT04425655University of California, San Diego2
已完成
2 期
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT01082939M.D. Anderson Cancer Center80
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
终止
2 期
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaMantle Cell LymphomaNCT00183989University of Southern California30